Skip to main content

Table 1 Major contributions to the development of targeted cancer immunotherapeutics against CTLA-4 and PD-1/PD-L1 Pathways a

From: PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

Contributions CTLA-4 PD-1 PD-L1 (B7-H1)
Gene Cloning Pierre Goldstein (1987) [59] Tasuku Honjo (1992) [57] Lieping Chen (1999) [47]
Inhibitory Function Jeffery Bluestone (1994) [30]
Arlene Sharpe (1995) [32]
Tak Mak (1995) [33]
Tasuku Honjo (1999) [60] Lieping Chen (1999) [47]
Tasuku Honjo, Clive Wood (2000) [57] b
Lieping Chen (2004) [68]
Ligand-receptor Interaction Peter Linsley (1991) [25] Tasuku Honjo, Clive Wood (2000) [57] b Tasuku Honjo, Clive Wood (2000) [57] b
Function in cancer immunity James Allison (1996) [34] NagahiroMinato (2002) [63]
Lieping Chen (2005) [70]
Tasuku Honjo (2005) [71]
Lieping Chen (2002) [56]
Nagahiro Minato (2002) [63]
  1. a The discovery of PD-L2 was made by Gordon Freeman and Arlene Sharpe (2001)[61], and Drew Pardoll (2001)[62]. Subsequent work on PD-L2 is not highlighted here
  2. b Gordon Freeman, Andrew Long and Yoshiko Iwai are the three co-first authors of this work, which renamed B7-H1 (its gene cloned one year earlier) to PD-L1